Skip to content

Gut-targeted Parkinson's therapies show selective benefits in pooled trials

Add-on therapies improved motor scores and bowel outcomes, while cognition, daily living and quality of life showed no statistically clear improvement.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Trials of therapies targeting gut microbes found improvements in motor symptom scores and constipation-related outcomes in people with Parkinson's disease. However, pooled results did not show statistically significant improvements in cognition, daily living or several other symptom measures. The findings suggest a limited pattern of benefit rather than improvement across the disease.

Keep in mind

The authors identify small samples and differences across studies. The abstract lacks treatment-specific results, comparator details, treatment lengths and adverse-event findings, limiting decisions about any particular approach.

THE NUMBERS, WITH CONTEXT

What researchers found

SMD -0.34 (95% CI -0.57 to -0.11)

Motor symptoms: MDS-UPDRS III

Adjunct gut-targeted therapies were evaluated; comparator treatments and assessment timing were not reported. The standardized motor score difference favored treatment and is not a percentage change.

Front Cell Infect Microbiol, 2025 · Original source ↓

Several approaches were considered

The review considered antibiotics, probiotics, synbiotics and fecal microbiota transplantation as additions to Parkinson's treatment. Grouping these approaches does not establish that each therapy has the same effects or works for the same patients.

Other outcomes remain uncertain

Cognitive tests, non-motor symptoms, quality of life and depression scores showed no statistically clear pooled improvement. A nonsignificant result does not prove no effect, and the abstract gives no outcome-specific evidence grades.

CHECK THE ORIGINAL

The original publication

Efficacy of gut microbiota-targeted therapies in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Gu X, Tang J, Chen C
Front Cell Infect Microbiol · 2025

PubMed ID
41078360
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.